Toggle light / dark theme

Famed longevity pioneer Aubrey de Grey, Chief Science Officer of SENS Research Foundation, joins Geoffrey Woo, Founder and Chairman of Health Via Modern Nutrition Inc., for an enlightening conversation about advances in longevity, the investments and technologies that extend life, and the challenges and opportunities of a world in which people live longer. He walks us through his damage repair therapies with a focus on rejuvenation, prevention, and wearable technologies. Filmed on May 17, 2021. To continue the discussion with fellow Real Vision members on this interview, click here to visit the Exchange: https://rvtv.io/2T7nqZL

Key Learnings: Longevity escape velocity, which is a term de Grey coined, is the idea in which life expectancy is extended longer than the time that is passing, and he estimates a 50% chance that aging could be brought under medical control in as little as 15 years’ time. To learn more about SENS’ research and advancements, please visit their site here: https://www.sens.org/.

Rapamycin has been proven to extend the lifespan of mice, warms and yeast. Lifespan.io is starting a large clinical trial named Participatory Evaluation (of) Aging (with) Rapamycin (for) Longevity Study, or PEARL, to see if the antiaging effects of Rapamycin apply to humans. This will be the first study to see if Rapamycin works as well in humans as it does in mice.

The PEARL trial will follow up to 200 participants over 12 months testing four different Rapamycin dosing regimens. It will be double-blind, randomized, placebo-controlled and registered with clinicaltrials.gov. The principal investigator is Dr. James P Watson at UCLA, who was also a PI for the famous TRIIM trial.

Tests and measurements will be taken, both after 6 and 12 months. These will include autonomic health tests, blood tests, body composition tests, fecal microbiome testing, immune and inflammation health tests, methylation age clock testing and skeletal muscle tests.

Interesting as I recall Aubrey lamenting that he had met Bezos several times over the years but never got a dime from him. Also I wonder where he would put the cash. Just donor all h by is SENS? Pick a company like Age-x?


Jeff Bezos is said to get into the Longevity Industry next month according to Aubrey De Grey. Having a billionaire invest into finding a cure for aging is both amazing and worrisome.
The field of longevity research was long underfunded but recently, with more and more results coming in, investors like Jeff Bezos are getting more and more interested in the field.

Last week, the most prominent figure in the longevity-research community, Aubrey The gray, has announced that one of the biggest event of this community will transpire in around a month. Previous investors were other tech entrepreneur like Peter Thiel or Googles Larry Page.

Every day is a day closer to the Technological Singularity. Experience Robots learning to walk & think, humans flying to Mars and us finally merging with technology itself. And as all of that happens, we at AI News cover the absolute cutting edge best technology inventions of Humanity.

If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile

TIMESTAMPS:
00:00 A Secret Investor?
00:53 Aubrey De Grey Interview.
01:49 The History of Longevity Investors.
04:08 Why invest in Longevity Research.
06:49 Last Words.

#aubreydegrey #longevity #jeffbezos

Hey guys — you might like this interview I did with Alex Steele about counter-ageing and the quest for biological immortality (focused around his new book ‘Ageless: The New Science of Getting Old Without Getting Older’. If you do very grateful for any subs to help support the channel!


I speak with Andrew Steele; author, scientist and anti-ageing campaigner about his book Ageless: The New Science of Getting Old Without Getting Older”. Interview covers why humans age, the growing anti-ageing movement, scientific progress over the past decade and potential anti-ageing treatments.

You can buy Andrew’s book here: https://www.amazon.co.uk/Ageless-Science-Getting-Older-Without/dp/152660826X

The third episode of our podcast, ImmortaliCast, is now available! We interviewed Didier Coeurnelle, chair and co-founder of HEALES, and Marion Steenacker, biologist from HEALES, who updated us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES. Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

You can watch this episode via YouTube or on the main podcast platforms:

#science #rejuvenation #aging #medicine #health #heales #lifespan #biology #plasma #HaroldKatcher #RodolfoGoya


In this interview for the podcast ImmortaliCast, Didier Coeurnelle, chair and co-founder of HEALES (https://heales.org/), and Marion Steenacker, biologist from HEALES, update us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES (https://heales.org/2020/12/22/studies-financed-by-heales-eff…er-2020/). Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

The Fable of the Dragon-Tyrant:

Papers referenced in the video:

Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk:
https://www.jacc.org/doi/10.1016/j.jacc.2020.10.

The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling:
https://www.sciencedirect.com/science/article/pii/S0753332220309781

Joint distribution of lipoprotein cholesterol classes. The Framingham study:
https://pubmed.ncbi.nlm.nih.gov/6573877/

Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS):
https://pubmed.ncbi.nlm.nih.gov/20223457/

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease:

Criticism of a recent video denouncing resveratrol.


Following Doctor Brad Stanfield’s latest ‘why I stopped video’, this last one about resveratrol and pterostilbene, many of you asked for my opinion, well here it is.

DoNotAge.org 10% Discount Code: MYNMN (https://bit.ly/3oaKgLv)
Alive by Science 10% Discount Code: MYNMN (https://bit.ly/3euiDd5)

I hope you enjoy my content and find it interesting or informative, hopefully both, if so, please consider supporting the channel by signing up to the one you prefer:

*Buy me a Kofi: https://ko-fi.com/mynmnexperiment.

Humans are distinguished from other species by several aspects of cognition. While much comparative evolutionary neuroscience has focused on the neocortex, increasing recognition of the cerebellum’s role in cognition and motor processing has inspired considerable new research. Comparative molecular studies, however, generally continue to focus on the neocortex. We sought to characterize potential genetic regulatory traits distinguishing the human cerebellum by undertaking genome-wide epigenetic profiling of the lateral cerebellum, and compared this to the prefrontal cortex of humans, chimpanzees, and rhesus macaque monkeys. We found that humans showed greater differential CpG methylation–an epigenetic modification of DNA that can reflect past or present gene expression–in the cerebellum than the prefrontal cortex, highlighting the importance of this structure in human brain evolution. Humans also specifically show methylation differences at genes involved in neurodevelopment, neuroinflammation, synaptic plasticity, and lipid metabolism. These differences are relevant for understanding processes specific to humans, such as extensive plasticity, as well as pronounced and prevalent neurodegenerative conditions associated with aging.

Citation: Guevara EE, Hopkins WD, Hof PR, Ely JJ, Bradley BJ, Sherwood CC (2021) Comparative analysis reveals distinctive epigenetic features of the human cerebellum. PLoS Genet 17: e1009506. https://doi.org/10.1371/journal.pgen.

Editor: Takashi Gojobori, National Institute of Genetics, JAPAN.